Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB

Shih Hsin Kan, Mika Aoyagi-Scharber, Steven Q. Le, Jon Vincelette, Kazuhiro Ohmi, Sherry Bullens, Daniel J. Wendt, Terri M. Christianson, Pascale M.N. Tiger, Jillian R. Brown, Roger Lawrence, Bryan K. Yip, John Holtzinger, Anil Bagri, Danielle Crippen-Harmon, Kristen N. Vondrak, Zhi Chen, Chuck M. Hague, Josh C. Woloszynek, Diana S. CheungKatherine A. Webster, Evan G. Adintori, Melanie J. Lo, Wesley Wong, Paul A. Fitzpatrick, Jonathan H. LeBowitz, Brett E. Crawford, Stuart Bunting, Patricia I. Dickson, Elizabeth F. Neufeld

Research output: Contribution to journalArticlepeer-review

63 Scopus citations


Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disease characterized by profound intellectual disability, dementia, and a lifespan of about two decades. The cause is mutation in the gene encoding α-N-acetylglucosaminidase (NAGLU), deficiency of NAGLU, and accumulation of heparan sulfate. Impediments to enzyme replacement therapy are the absence of mannose 6-phosphate on recombinant human NAGLU and the blood-brain barrier. To overcome the first impediment, a fusion protein of recombinant NAGLU and a fragment of insulin-like growth factor II (IGFII) was prepared for endocytosis by the mannose 6-phosphate/IGFII receptor. To bypass the blood-brain barrier, the fusion protein ("enzyme") in artificial cerebrospinal fluid ("vehicle") was administered intracerebroventricularly to the brain of adult MPS IIIB mice, four times over 2 wk. The brains were analyzed 1-28 d later and compared with brains of MPS IIIB mice that received vehicle alone or control (heterozygous) mice that received vehicle. There was marked uptake of the administered enzyme in many parts of the brain, where it persisted with a half-life of approximately 10 d. Heparan sulfate, and especially disease-specific heparan sulfate, was reduced to control level. A number of secondary accumulations in neurons [β-hexosaminidase, LAMP1(lysosome-associated membrane protein 1), SCMAS (subunit c of mitochondrial ATP synthase), glypican 5, β-amyloid, P-tau] were reduced almost to control level. CD68, a microglial protein, was reduced halfway. A large amount of enzymealso appeared in liver cells,where it reduced heparan sulfate and β-hexosaminidase accumulation to control levels. These results suggest the feasibility of enzyme replacement therapy for MPS IIIB.

Original languageEnglish
Pages (from-to)14870-14875
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number41
StatePublished - Oct 14 2014


Dive into the research topics of 'Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB'. Together they form a unique fingerprint.

Cite this